Other languages Medivir AB

Equities

MVIR B

SE0020181014

Delayed Nasdaq Stockholm Other stock markets 08:16:27 2024-04-29 EDT			5-day change	1st Jan Change
3.16 ^SEK	-2.47%		+10.88%	+10.88%

04-25	Medivir Gets Two US FDA Designations for MIV-711	MT
03-21	Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medivir Presents Data That Strengthens the Fostrox/Lenvima Combination in Primary Liver Cancer At Easl Liver Cancer Summit	02-22
Medivir AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-15
Medivir AB Reports Earnings Results for the Full Year Ended December 31, 2023	02-15
Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress	01-18
Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer	01-17
Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers	12-19
Medivir AB Agrees with Lonza to Manufacture a Fostrox GMP Campaign, to Be Tested in 2L HCC with Intent to Commercialize Via Accelerated Approval	12-13
Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC	11-27
Medivir AB to Present Clinical Data at ASCO-GI with Fostrox + Lenvima in HCC and Shares Positive Response from Type D Meeting with FDA	11-13
Medivir AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-27
Medivir AB to Report New and Updated Data from Ongoing Phase 2a HCC Study as Part of Its Third Quarter Report on Friday	23-10-25
Medivir AB Appoints Nomination Committee	23-10-23
Medivir AB Announces Resignation of Anette Lindqvist as Director	23-10-20
Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle	23-10-05
Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima	23-09-04
Medivir AB Announces Formation of A Scientific Advisory Council	23-08-07
Medivir AB Announces Patent Application for Fostrox Approval in China	23-06-19
Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima	23-06-02
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27
Medivir Presents New Data At AACR Showing Significantly Improved Antitumor Efficacy in Non Clinical Tumor Models with fostrox in Triple Combination	23-04-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Medivir AB

Equities

MVIR B

SE0020181014

Other languages

Filters